BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 238 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2024. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $16,011,521 | +225.7% | 2,590,861 | +167.7% | 0.06% | +233.3% |
| Q1 2024 | $4,916,028 | -24.1% | 967,722 | -10.5% | 0.02% | -30.8% |
| Q4 2023 | $6,479,060 | +166.1% | 1,081,646 | +214.6% | 0.03% | +116.7% |
| Q3 2023 | $2,434,444 | +278.4% | 343,848 | +276.2% | 0.01% | +300.0% |
| Q2 2023 | $643,435 | -88.5% | 91,397 | -86.4% | 0.00% | -89.3% |
| Q1 2023 | $5,615,030 | +84.4% | 673,265 | +153.9% | 0.03% | +64.7% |
| Q4 2022 | $3,044,691 | +46.9% | 265,217 | +108.0% | 0.02% | +41.7% |
| Q1 2022 | $2,073,000 | -78.4% | 127,510 | -81.6% | 0.01% | -77.4% |
| Q4 2021 | $9,610,000 | -43.3% | 693,830 | -41.2% | 0.05% | -51.4% |
| Q3 2021 | $16,961,000 | +87.4% | 1,180,297 | +106.2% | 0.11% | +73.0% |
| Q2 2021 | $9,049,000 | +16.9% | 572,378 | -44.9% | 0.06% | -3.1% |
| Q4 2020 | $7,740,000 | +7488.2% | 1,038,874 | +2814.4% | 0.06% | +3150.0% |
| Q3 2019 | $102,000 | -79.4% | 35,646 | -72.6% | 0.00% | -85.7% |
| Q2 2019 | $494,000 | +384.3% | 130,300 | +942.0% | 0.01% | +366.7% |
| Q1 2019 | $102,000 | – | 12,505 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $50,998,000 | 20.86% |
| RTW INVESTMENTS, LP | 3,458,120 | $29,048,000 | 7.65% |
| ISZO CAPITAL MANAGEMENT LP | 307,366 | $2,582,000 | 4.49% |
| DAFNA Capital Management LLC | 541,128 | $4,545,000 | 3.84% |
| RA Capital Management | 3,489,795 | $29,314,000 | 3.60% |
| EMORY UNIVERSITY | 375,348 | $3,153,000 | 2.98% |
| Ghost Tree Capital, LLC | 1,500,000 | $12,600,000 | 2.35% |
| ACUTA CAPITAL PARTNERS, LLC | 920,310 | $7,731,000 | 1.83% |
| Avoro Capital Advisors LLC | 1,603,001 | $13,465,000 | 1.72% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,085,236 | $25,916,000 | 1.00% |